Can I read Section 4: Clinical pharmacy services on EtoBox?

Section 4: Clinical pharmacy services by Rodriguez Mauriz, R (author);Seguí Solanes, C (author);Almendros-Abad, N (author);Sosa-Pons, A (author);Rudi Sola, N (author) is a nonfiction available to read on EtoBox.

What is Section 4: Clinical pharmacy services about?

age of the patients were collected. Adalimumab's persistence was calculated in months from the beginning of treatment to the last dispensation register. We collected dispensation data from January 2007 to May 2019 to calculate adalimumab's persistence until this date. The drug's survival was calculated using the Kaplan-Meier method and the log rank test to compare survival in each of the pathologies. A significant difference was considered with a p value <0.05. Results 125 patients started treatment with adalimumab between January 2007 and December 2016; 48 patients (38.4%) were diagnosed with rheumatoid arthritis, 43 (34.4%) with ankylosing spondylitis and 34 (27.2%) with psoriasis arthritis. 52.1% of all patients were naïve for biological drug treatments. 83.3%, 48.8% and 52.9% were women aged 57.6 ±43.8, 47.1±10.1 and 55.6 ±14.0 years in the rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis groups, respectively. After analysing the data using the Kaplan-Meier method, we obtained an overall survival of adalimumab in each pathology, which was greatest in psoriatic arthritis with 59.9 months (95% CI 39.6 to 80,2), followed by 46.8 months in rheumatoid arthritis (

Who reads Section 4: Clinical pharmacy services?

Author

Rodriguez Mauriz, R (author);Seguí Solanes, C (author);Almendros-Abad, N (author);Sosa-Pons, A (author);Rudi Sola, N (author)

Publisher

British Medical Journal Publishing Group

Published

2021

Language

EN

Category

nonfiction